
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis
AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ 15 mg, once daily) for the treatment of adult patients with giant cell arteritis (GCA). GCA is an autoimmune disease of medium and large arteries...